Case Report

Primary immune deficiency in the intensive care unit: It is never too late to diagnose and treat

Rucha S. Dagaonkar, Tiyas Sen, Zarir F. Udwadia, Mukesh B. Desai

Abstract

Common variable immunodeficiency disorders (CVIDs), a heterogeneous group of primary immune deficiencies, can present at all age. Our patient with a hitherto undiagnosed CVID, symptomatic since middle ages, presented with severe pneumonia. Specific management of his CVID in addition to standard therapy was life-saving.

Keywords: Adult primary immune deficiency, common variable immune deficiency, intravenous immunoglobulin, late onset common immunoodeficiency, non-resolving pneumonia

Introduction

Common variable immunodeficiency disorders (CVIDs) are a heterogeneous group of immune deficiencies characterized by hypogammaglobulinemia. The diagnostic criteria are: History of recurrent infections, decreased IgG levels (less than two standard deviations below the lowest normal level), one more immunoglobulin deficiency, and failure to mount sufficient antibody response to antigen challenge (with pneumococcal or HiB vaccines). Pulmonary complications are common. We report a case of severe pneumonia eventually diagnosed to have a CVID.

Case Report

A 42-year-old man presented to our center with high-grade fever, chills, productive cough since six weeks, weight loss (6 kg over four weeks), and diarrhea since two weeks.

In mid-July, a chest radiograph (CXR) showed right middle zone consolidation. Sputum culture grew Klebsiella pneumoniae. Antibiotics were started (levofloxacin, amikacin, metronidazole, fluconazole) without response, at another center. Empiric antituberculosis therapy (ATT) was started.

When there was no response, he was referred to our hospital (13/9/09).

He was asymptomatic until 5 years ago after which he had recurrent upper respiratory tract infections (RTIs) since 2005: pneumonia (2006), and was treated for pulmonary tuberculosis twice (2005, 2007). Since 2007, he had monthly episodes of watery diarrhea. Childhood and family history were insignificant.

Examination revealed fever, tachycardia, tachypnea (respiratory rate 36/ min), blood pressure of 110/60, and bilateral crepitations on chest auscultation. PaO2 was 58 mm Hg on arterial blood gas analysis.

He was admitted to the intensive care unit (ICU) where CXR showed right middle and lower zone consolidation. Non-resolving pneumonia (NRP) was diagnosed and meropenem and levofloxacin were started, ATT being discontinued.
Endotracheal intubation was soon required. By day 5 in ICU, CXR showed bilateral alveolar shadows with PaO$_2$/FiO$_2$ of 59/1 (<200). Ventilation with ARDS protocol was started. Noradrenaline was given at ceiling doses. Antibiotics were changed (targocid, colistin) as per sensitivity reports, and empiric amphotericin-B was added. Trimethoprim-cotrimoxazole prophylaxis was started.

Underlying primary immune deficiency (PID), a CVID, was suspected. Intravenous immunoglobulin (IVIG) was given (2 g/kg on 21/9/09), over five days for the hypogammaglobulinemia [Table 1].

By day 2 of IVIG administration, the patient became afebrile for the first time in eight weeks. FiO$_2$ requirements reduced (35% by 6/10/09). Tracheostomy was done (30/10/09), with subsequent decannulation (26/10/09). CXR showed clearing of alveolar shadows, with residual bronchiectasis. He was ambulatory on discharge (December) and follows up (irregularly, due to cost constraints) for replacement IVIG and chest physiotherapy.

**Discussion**

Our initial diagnosis was an NRP with Gram-negative sepsis.

Serum immunoglobulin level measurement done as a part of the workup for NRP [Table 1] showed hypogammaglobulinemia. Low CD4 T lymphocyte counts suggested T lymphocyte dysfunction. HIV infection was ruled out. There was also history of recurrent RTIs and diarrhea, beginning 5 years prior to presentation. There was infection with two organisms (Klebsiella pneumonia and Pseudomonas aeruginosa) at presentation. These points suggested an underlying adult-onset PID with antibody deficiency,[4] and possibly, T lymphocyte dysfunction.[5]

High-dose IVIG was commenced (2 g/kg loading dose, over 5 days), as serum IgG levels were undetectable,[6] and significant improvement followed, within 72 hours. Although theoretically this could be attributed to the effect of IVIG on systemic inflammatory response in sepsis,[6,7] repeat IgG levels, after 8 and 12 weeks of loading dose, continued to decline [Table 2], improving only after replacement doses (0.4 g/kg) were given, thus confirming the diagnosis of a CVID.[1]

Recurrent RTIs are the most common manifestation in CVIDs,[3,4,8] complicated with sequelae like chronic sinusitis, lung fibrosis, and bronchiectasis (12.2%).[6] Granulomatous Interstitial Lung Disease can shorten survival in CVIDs.[9] Other manifestations include autoimmune phenomena and systemic lymphocytic infiltration. Antibody deficiency[10] predisposes to infections with encapsulated bacteria. This is preventable with regular IVIG replacement.[2]

Treatment of hypogammaglobulinemia is replacement with a monthly dose of 0.4 g/kg, even on outpatient basis.[2,11,12] Maintenance of serum IgG trough level >0.8 g/l, in patients with pulmonary complications is recommended.[6] Antibody failure precludes the use of vaccines.[2]

It is a common misconception that PIDs are mainly a pediatric problem. CVIDs can present at any age, with onset peaking in the first and third decades.[1] Our patient became symptomatic in the fourth decade (age 37 years), and was diagnosed in the fifth decade (age 42 years). He also had low CD4 lymphocyte counts. He could therefore fall into the late-onset common immune deficiency category, as per the DEFI study.[8]

NRPs occur even in immunocompetent patients, frequently causing sepsis. ICU mortality of severe pneumonias was 36.8% in one series.[8] PIDs may easily be missed as a cause of NRPs, as other causes (malnutrition, HIV infection, tuberculosis, inappropriate use of antibiotics) are common, while the exact incidence

---

**Table 1: Laboratory data**

| Culture       | Normal laboratory values |
|---------------|--------------------------|
| Blood and tracheal aspirate |  |
| Klebsiella pneumonia |  |
| Pseudomonas aeruginosa (both) |  |
| HIV ELISA | Negative |
| HIV RNA PCR | Not detected |
| Serum Immunoglobulin (g/l) |  |
| IgA | Undetectable | 8.1-36.9 |
| IgG | Undetectable | 7.36-11.95 |
| IgM | 0.052 | 0.62 |
| Total Leukocyte count ($\times 10^9$/l) | Between 10 and 15 | 4 – 10 |
| T Lymphocytes (cells/microl) |  |
| CD3+ | 641 | 767-2786 |
| CD4+ | 203 | 350-1048 |
| CD8+ | 393 | 230-1195 |
| CD19+ | 402 | 125-707 |

**Table 2: IgG levels on follow-up**

| Date          | Serum IgG (g/dl) | Replacement (g/kg) |
|---------------|------------------|---------------------|
| 14/9/09       | Undetectable    | 21/9/09: 2 (loading dose) |
| 26/10/09      | 8.40            |                      |
| 20/11/09      | 6.02 (low)      | 0.4                  |
| 14/12/09 (discharge) | 8.45 | 0.4                  |
| 7/4/10        | 2.67 (low)      | 0.4                  |
of CVIDs is unknown, although it is the most common PID encountered in clinical practice.[2,4,11]

The pneumonia in our patient deteriorated despite appropriate antibiotics, mechanical ventilation, and inotropes, improving only when his underlying PID was diagnosed and treated.

The learning point that emerges is, CVIDs are an important cause of severe pneumonia even in adults. Correct diagnosis and prompt treatment of the underlying CVIDs, even in patients on maximum life support, can reduce the mortality of severe pneumonia.

References
1. Geha RS, Notarangelo LD, Casanova JL, Chapel H, Conley ME, Fischer A, et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007;120:776-94.
2. Bergbreiter A, Salzer U. Common variable immunodeficiency: A multifaceted and puzzling disorder. Expert Rev Clin Immunol 2009;5:167-80.
3. Aghamohammadi A, Pouladi N, Parvaneh N, Yeganeh M, Movahedi M, Gharagolou M, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr 2007;53:32-8.
4. Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: An update on etiology and management. Immunol Allergy Clin North Am 2008;28:367-86, ix-x.
5. Malphettes M, Gérard L, Carmagnat M, Mouillot G, Vinee N, Boutiloul D, et al. Late-onset combined immune deficiency: A subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009;49:1329-38.
6. Orange JS, Hassay EM, Weiler CR, Bullow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 Suppl):862-53.
7. Hartung HP, Mounthou L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)—beyond immunodeficiencies and neurology. Clin Exp Immunol 2009;158 Suppl 1:23-33.
8. Marques MR, Nunes A, Sousa C, Moura F, Gouveia J, Ramos A. Community-acquired pneumonia in an intensive care unit. Rev Port Pneumol 2010;16:223-35.
9. Bates CA, Ellison MC, Lynch DA, Cool CD, Brown KK, Routes JM. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol 2004;114:415-21.
10. Bonhomme D, Hammarström L, Webster D, Chapel H, Hermine O, Le Deist F, et al. Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol 2006;165:4725-30.
11. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010;116:7-15.
12. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28:737-64.

How to cite this article: Dagaonkar RS, Sen T, Udwadia ZF, Desai MB. Primary immune deficiency in the intensive care unit: It is never too late to diagnose and treat. Indian J Crit Care Med 2011;15:179-81.

Source of Support: Nil, Conflict of Interest: None declared.

New features on the journal’s website

Optimized content for mobile and hand-held devices
HTML pages have been optimized for mobile and other hand-held devices (such as iPad, Kindle, iPod) for faster browsing speed. Click on [Mobile Full text] from Table of Contents page. This is simple HTML version for faster download on mobiles (if viewed on desktop, it will be automatically redirected to full HTML version).

E-Pub for hand-held devices
E-Pub is an open e-book standard recommended by The International Digital Publishing Forum which is designed for reflowable content i.e. the text display can be optimized for a particular display device. Click on [EPub] from Table of Contents page. There are various e-Pub readers such as for Windows: Digital Editions, OS X: Calibre/Bookworm, iPhone/iPod Touch/iPad: Stanza, and Linux: Calibre/Bookworm.

E-Book for desktop
One can also see the entire issue as printed here in a ‘flip book’ version on desktops. Links are available from Current Issue as well as Archives pages. Click on View as eBook.